An interventional study of Test toothpaste and Colgate Cavity Protection Toothpaste in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by HALEON · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this 4-week clinical study is to evaluate the ability of an experimental toothpaste, containing 0.454 percent (%) Stannous Fluoride (SnF2), 0.3% Zinc Chloride (ZnCl2) and 1% Alumina, to improve gingival health and plaque accumulation compared to a regular fluoride toothpaste (negative control) in participants with plaque-induced mild to moderate gingivitis.
This will be a single-center, 4 weeks, randomized, controlled, examiner-blind, 2 treatment arms, stratified, parallel group design clinical study, investigating gingival health and supra-gingival plaque reduction on healthy participants after using an experimental toothpaste containing 0.454% SnF2, 0.3% ZnCl2 and 1% Alumina. Sufficient participants will be screened so that at least 160 participants are randomized (approximately 80 per group) to ensure approximately 144 (approximately 72 per group) evaluable participants complete the entire study.
354 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.
This study's enrollment of 175 is above the median of 55 across 317 interventional studies indexed under Dental Plaque.
Browse Dental Plaque studies →HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At Screening (Visit 1):
At Baseline (Visit 2):
Exclusion Criteria:
Medications exclusions: At Screening (Visit 1):
Medications exclusions: At Baseline (Visit 2):
Periodontal exclusions:
Dental Exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will brush their teeth with full ribbon of test toothpaste on head of toothbrush for one timed minute twice a day (morning and evening) for 4 weeks.
Drug: Test toothpaste
Participants will brush their teeth with full ribbon of reference toothpaste (Colgate Cavity Protection) on head of toothbrush for one timed minute twice a day (morning and evening) for 4 weeks.
Drug: Colgate Cavity Protection Toothpaste
0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.
Commercial toothpaste containing 1450 ppm fluoride.
Adjusted Mean Bleeding Index (BI) at Week 4
The BI is an invasive assessment of gingival bleeding performed using a round-end probe. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. BI was assessed on 3-points scale ranging from 0 to 2, where 0= Absence of bleeding on probing, 1= Bleeding observed within 30 seconds of probing, 2= Bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.
Time frame: Week 4
Adjusted Mean Number of Bleeding Sites (NBS) at Week 4
The bleeding assessment was done using round-end probe. The number of bleeding sites for each participant= the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Adjusted mean value was derived using ANCOVA model.
Time frame: Week 4
Adjusted Mean Modified Gingival Index (MGI) at Week 4
The MGI is a non-invasive visual assessment of gingival inflammation. MGI was assessed for all evaluable surfaces, four sites per tooth and was scored on a 5-point scale ranging from 0 to 4, where 0= Absence of inflammation, 4= Severe inflammation. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.
Time frame: Week 4
Adjusted Mean Overall Turesky Plaque Index (TPI) at Week 4
The TPI is a non-invasive assessment of supra-gingival plaque accumulation. The plaque was disclosed using a plaque disclosing dye solution and the TPI was assessed using a 6-point scale ranging from 0 to 5, where 0= No plaque, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.
Time frame: Week 4
Adjusted Mean Interproximal TPI at Week 4
The TPI is a non-invasive assessment of supra-gingival plaque accumulation. The plaque was disclosed using a plaque disclosing dye solution and the TPI was assessed using a 6-point scale ranging from 0 to 5, where 0= No plaque, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.
Time frame: Week 4
This study was conducted at a single center in United Kingdom.
| Milestone | Test Toothpaste | Reference Toothpaste (Negative Control) |
|---|---|---|
| Started | 80 | 81 |
| Completed | 76 | 78 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The BI is an invasive assessment of gingival bleeding performed using a round-end probe. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. BI was assessed on 3-points scale ranging from 0 to 2, where 0= Absence of bleeding on probing, 1= Bleeding observed within 30 seconds of probing, 2= Bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.
| score on a scale | Test Toothpaste | Reference Toothpaste (Negative Control) |
|---|---|---|
| Adjusted Mean Bleeding Index (BI) at Week 4 | 0.19 ± 0.013 | 0.21 ± 0.013 |
The bleeding assessment was done using round-end probe. The number of bleeding sites for each participant= the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Adjusted mean value was derived using ANCOVA model.
| bleeding sites | Test Toothpaste | Reference Toothpaste (Negative Control) |
|---|---|---|
| Adjusted Mean Number of Bleeding Sites (NBS) at Week 4 | 30.0 ± 1.96 | 32.5 ± 1.93 |
The MGI is a non-invasive visual assessment of gingival inflammation. MGI was assessed for all evaluable surfaces, four sites per tooth and was scored on a 5-point scale ranging from 0 to 4, where 0= Absence of inflammation, 4= Severe inflammation. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.
| score on a scale | Test Toothpaste | Reference Toothpaste (Negative Control) |
|---|---|---|
| Adjusted Mean Modified Gingival Index (MGI) at Week 4 | 1.79 ± 0.011 | 1.83 ± 0.010 |
The TPI is a non-invasive assessment of supra-gingival plaque accumulation. The plaque was disclosed using a plaque disclosing dye solution and the TPI was assessed using a 6-point scale ranging from 0 to 5, where 0= No plaque, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.
| score on a scale | Test Toothpaste | Reference Toothpaste (Negative Control) |
|---|---|---|
| Adjusted Mean Overall Turesky Plaque Index (TPI) at Week 4 | 2.64 ± 0.037 | 2.62 ± 0.036 |
The TPI is a non-invasive assessment of supra-gingival plaque accumulation. The plaque was disclosed using a plaque disclosing dye solution and the TPI was assessed using a 6-point scale ranging from 0 to 5, where 0= No plaque, 5= Plaque covering 2/3 or more of the crown of the tooth. Lower score indicated improvement in the symptoms. Adjusted mean value was derived using ANCOVA model.
| score on a scale | Test Toothpaste | Reference Toothpaste (Negative Control) |
|---|---|---|
| Adjusted Mean Interproximal TPI at Week 4 | 3.03 ± 0.039 | 3.03 ± 0.038 |
Collected over From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 69 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Toothpaste | 0/78 (0%) | 0/78 (0%) | 13/78 (16.7%) |
| Reference Toothpaste (Negative Control) | 0/83 (0%) | 0/83 (0%) | 6/83 (7.2%) |
| Event | Test Toothpaste | Reference Toothpaste (Negative Control) |
|---|---|---|
| ORAL MUCOSAL EXFOLIATIONGastrointestinal disorders | 4/78 | 2/83 |
| HYPERAESTHESIA TEETHGastrointestinal disorders | 2/78 | 1/83 |
| ORAL DISCOMFORTGastrointestinal disorders | 2/78 | 0/83 |
| TONGUE ULCERATIONGastrointestinal disorders | 1/78 | 1/83 |
| GINGIVAL PAINGastrointestinal disorders | 1/78 | 0/83 |
| MOUTH ULCERATIONGastrointestinal disorders | 1/78 | 0/83 |
| PARAESTHESIA ORALGastrointestinal disorders | 1/78 | 0/83 |
| SALIVARY HYPERSECRETIONGastrointestinal disorders | 1/78 | 0/83 |
| STOMATITISGastrointestinal disorders | 1/78 | 0/83 |
| SWOLLEN TONGUEGastrointestinal disorders | 1/78 | 0/83 |
Safety Population comprised of all randomized participants who received at least one dose of the investigational product. Post randomization, two participants (from test group) received incorrect study product (i.e. Reference product). The Safety Population is presented using actual study product received and thus, the Overall Number of Baseline Participants in "Reference Toothpaste (Negative Control)" is greater than the number of participants included in the Participant Flow module.
| Age, Continuous(years) | Test Toothpaste | Reference Toothpaste (Negative Control) | Total |
|---|---|---|---|
| Mean | 27.0 ± 11.75 | 27.9 ± 11.76 | 27.5 ± 11.73 |
| Sex: Female, Male(Participants) | Test Toothpaste | Reference Toothpaste (Negative Control) | Total |
|---|---|---|---|
| Female | 44 | 44 | 88 |
| Male | 34 | 39 | 73 |
| Ethnicity (NIH/OMB)(Participants) | Test Toothpaste | Reference Toothpaste (Negative Control) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 78 | 83 | 161 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Test Toothpaste | Reference Toothpaste (Negative Control) | Total |
|---|---|---|---|
| African American/African Heritage | 5 | 3 | 8 |
| Asian - Central/South Asian Heritage | 26 | 29 | 55 |
| Asian - East Asian Heritage | 4 | 6 | 10 |
| Asian - South East Asian Heritage | 6 | 6 | 12 |
| White - Arabic/North African Heritage | 3 | 7 | 10 |
| White - White/Caucasian/European Heritage | 29 | 28 | 57 |
| Multiple | 5 | 4 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
Ran from Sep 2024 to primary completion in Dec 2024, 2 months.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 2 months is close to that.
Counting every sponsor, half of 179 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.